Exploring ways to improve CDI outcomes.

Details

Serval ID
serval:BIB_D9A97DB247AF
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Exploring ways to improve CDI outcomes.
Journal
Medecine et maladies infectieuses
Author(s)
Galpérine T., Guery B.
Working group(s)
French Group of Fecal Microbiota Transplantation (GFTF)
ISSN
1769-6690 (Electronic)
ISSN-L
0399-077X
Publication state
Published
Issued date
02/2018
Peer-reviewed
Oui
Volume
48
Number
1
Pages
10-17
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Clostridium difficile is an anaerobic spore-forming Gram-positive bacillus recognized as an evolving international health problem. Metronidazole and vancomycin were - until recently - the only drugs available to treat C. difficile infection (CDI). Better knowledge of the pathophysiology and the development of new drugs completely modified the management of initial episodes and recurrences of CDI. Fidaxomicin significantly reduced recurrences compared with vancomycin. New drugs are also currently evaluated (cadazolid, surotomycin, ridinilazole, rifaximin). Gut microbiota homeostasis was clearly shown to be a key determinant in recurrences as demonstrated by the development of gut microbiota transplantation and alternative microbiota substitution. Passive immunotherapy and vaccinal approaches are also currently being evaluated. In conclusion, CDI treatment has evolved with the development of new therapeutic pathways which now need to be implemented in international guidelines.

Keywords
Antibiotics, Antibiotiques, Clostridium difficile, Fecal microbiota transplantation, Transplantation fécale, Vaccin, Vaccine
Pubmed
Web of science
Create date
25/01/2018 20:45
Last modification date
20/08/2019 15:58
Usage data